Develop therapeutics for rare diseases. Focus on Duchenne muscular dystrophy (DMD) and cystic fibrosis. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
There is $328.1M in the vault; even if every debt were paid off, $322.8M would remain.
A loss of $94.3M against $0 in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown, the price history.